Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
| Autor: | Kirk V. Shepard, Bienvenido G. Yangco, Javier O. Morales, Lewis Lefkowitz, Linda Laubenstein, Paul Bellman, Terry F. Plasse, Jeffrey E. Beal, Richard Olson |
|---|---|
| Rok vydání: | 1995 |
| Předmět: |
Adult
Male medicine.medical_specialty Visual analogue scale Nausea media_common.quotation_subject Anorexia Placebo Gastroenterology Cachexia Double-Blind Method Weight loss Internal medicine Weight Loss medicine Humans Dronabinol General Nursing media_common Acquired Immunodeficiency Syndrome business.industry Appetite Middle Aged medicine.disease Surgery Anesthesiology and Pain Medicine Female Neurology (clinical) medicine.symptom business |
| Zdroj: | Journal of Pain and Symptom Management. 10:89-97 |
| ISSN: | 0885-3924 |
| Popis: | The effects of dronabinol on appetite and weight were evaluated in 139 patients with AIDS-related anorexia and > or = 2.3 kg weight loss in a multi-institutional study. Patients were randomized to receive 2.5 mg dronabinol twice daily or placebo. Patients rated appetite, mood, and nausea by using a 100-mm visual analogue scale 3 days weekly. Efficacy was evaluable in 88 patients. Dronabinol was associated with increased appetite above baseline (38% vs 8% for placebo, P = 0.015), improvement in mood (10% vs -2%, P = 0.06), and decreased nausea (20% vs 7%; P = 0.05). Weight was stable in dronabinol patients, while placebo recipients had a mean loss of 0.4 kg (P = 0.14). Of the dronabinol patients, 22% gained > or = 2 kg, compared with 10.5% of placebo recipients (P = 0.11). Side effects were mostly mild to moderate in severity (euphoria, dizziness, thinking abnormalities); there was no difference in discontinued therapy between dronabinol (8.3%) and placebo (4.5%) recipients. Dronabinol was found to be safe and effective for anorexia associated with weight loss in patients with AIDS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect